EUVIMEDScopri EUVIMED
Randomisierte kontrollierte StudieKlinische Studie (Phase II)

Research Communication: Teriflunomide Does Not Affect Gluten‐Specific T‐Cell Activity in Coeliac Disease—A Randomised, Placebo‐Controlled Trial

Louise F Risnes iD, Margit Brottveit, Ida Robertsen, Jostein Ibsen, Lars Aabakken, Marie K Johannesen, Stine R Lund, Siv K B Furholm, Siv E H Isaksen, Anders Åsberg, Ludvig M Sollid, Knut E A Lundin

Alimentary Pharmacology & Therapeutics · 2025

DOI: 10.1111/apt.70301 ↗

At a glance

Randomisierte kontrollierte Studie in Alimentary Pharmacology & Therapeutics, 2025. Written by Louise F Risnes and 11 co-authors. Institution: Norwegian Centre for Coeliac Disease Research, University of Oslo, Oslo, Norway. Major MEDLINE topics: Celiac Disease, Toluidines, Crotonates, Glutens. Cited 1 times so far (Crossref); 10 references. Funded by: Aktieselskabet Freia Chocolade Fabriks Medisinske fond, Stiftelsen K.G. Jebsen, Oslo University Hospital.

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

Coeliac disease is an autoimmune disorder driven by gluten and managed through a strict gluten‐free diet. We tested teriflunomide, a drug known for its ability to alter T‐cell activity, in a phase 2a trial of 15 patients with coeliac disease. Participants received teriflunomide or placebo including a loading dose, followed by a 3‐day oral gluten challenge to monitor T‐cell responses. The main aim was to observe attenuation of gluten‐specific T‐cell activation markers after gluten exposure. We found no significant differences in T‐cell activity between groups, concluding that teriflunomide is ineffective as a non‐dietary treatment for coeliac disease.

Subjects

MeSH terms (MEDLINE)

Celiac DiseaseToluidinesCrotonatesGlutensT-LymphocytesHumansNitrilesHydroxybutyratesMaleFemaleAdultMiddle AgedDiet, Gluten-FreeDouble-Blind Method

Substances

NitrilesteriflunomideHydroxybutyratesToluidinesCrotonatesGlutens

Authors and institutions

  • Norwegian Centre for Coeliac Disease Research, University of Oslo, Oslo, Norway.
  • Department of Immunology, Oslo University Hospital-Rikshospitalet, Oslo, Norway.
  • Department of Transplantation Medicine, Oslo University Hospital-Rikshospitalet, Oslo, Norway.
  • Department of Gastroenterology, Oslo University Hospital-Ullevål, Oslo, Norway.
  • Department of Pharmacy, University of Oslo, Oslo, Norway.

ORCID profiles: Louise F Risnes

Funding

  • Aktieselskabet Freia Chocolade Fabriks Medisinske fond
  • Stiftelsen K.G. Jebsen
  • Oslo University Hospital
  • Universitetet i Oslo
  • Oslo universitetssykehus HF

Cite

APA

Risnes, L. F., Brottveit, M., Robertsen, I., Ibsen, J., Aabakken, L., Johannesen, M. K., Lund, S. R., Furholm, S. K. B., Isaksen, S. E. H., Åsberg, A., Sollid, L. M., & Lundin, K. E. A. (2025). Research Communication: Teriflunomide Does Not Affect Gluten‐Specific T‐Cell Activity in Coeliac Disease—A Randomised, Placebo‐Controlled Trial. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.70301

Vancouver

Risnes LF, Brottveit M, Robertsen I, Ibsen J, Aabakken L, Johannesen MK, et al. Research Communication: Teriflunomide Does Not Affect Gluten‐Specific T‐Cell Activity in Coeliac Disease—A Randomised, Placebo‐Controlled Trial. Alimentary Pharmacology & Therapeutics. 2025. doi:10.1111/apt.70301

BibTeX
@article{Risnes2025,
  author = {Risnes, Louise F and Brottveit, Margit and Robertsen, Ida and Ibsen, Jostein and Aabakken, Lars and Johannesen, Marie K and Lund, Stine R and Furholm, Siv K B and Isaksen, Siv E H and Åsberg, Anders and Sollid, Ludvig M and Lundin, Knut E A},
  title = {Research Communication: Teriflunomide Does Not Affect Gluten‐Specific T‐Cell Activity in Coeliac Disease—A Randomised, Placebo‐Controlled Trial},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2025},
  doi = {10.1111/apt.70301}
}
Start for free →